For tumor tissue selectivity, enzymes of non-human origin are needed. This results in severe problems including:

  • – Immunogenicity

– Creates intolerable immune reactions and side effects
– Immune response interferes with therapy rendering it ineffective

  • – Instability in serum
  • – Limited residence time in the body
  • – Limited tumor localization

Solution must simultaneously meet all these criteria:

1. Hide the enzymes from the immune system
2. While hidden, enzymatic activity must be maintained
3. Hiding system must be small enough for long in-vivo residence
4. Hiding system must be biologically inert and biodegradable
5. Hiding system must be targetable

DevaCell’s SHELS technology meets all